22 September 2023
Swissmedic approves Moderna Switzerland GmbH coronavirus vaccine Spikevax XBB.1.5
Swissmedic's review of the data packages submitted found that the vaccine met the requirements for a COVID variant-adapted vaccine. It is administered as a single dose of 0.5 mL (50 micrograms per dose, dispersion for injection). The vaccine encodes the spike protein for Omicron subvariant XBB.1.5 of SARS-CoV-2. As with previous authorised coronavirus variant-adapted vaccines, no new safety signals have been detected.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar